d44

D44 is a Plasmodium FKBPs inhibitor.

HA-CD44 interaction inhibitor 1 is an anti-tumor agent, which is a hyaluronic acid inhibitor targeting CD44. HA-CD44 interaction inhibitor 1 can inhibit MDA-MB-231 cells with an EC50 of 1.77 μM.

HA-CD44 interaction inhibitor 3 (compound 5d) is an inhibitor of the Hyaluronic acid (HA)-CD44 interaction. It has inhibitory effects on MDA-MB-231 (CD44++) cells and MCF-7 (CD44--) cells with EC50 values of 4.24 μM and 14.74 μM, respectively. HA-CD44 interaction inhibitor 3 is applicable to cancer research.

NPD4456 (Compound 3) is a 3-phenylcoumarin Vpr inhibitor. It binds competitively to Vpr and inhibits HIV-1 virus infection.

KBD4466 is a potent oral inhibitor of TLR7 and TLR8, with IC50 values of 0.9 nM and 2.8 nM, respectively. This compound effectively suppresses the inflammatory cytokines IL-6 and IFN-α. KBD4466 has shown to improve disease progression and increase survival rates in the BXSB/MpJ mouse model of systemic lupus erythematosus (SLE). It is suitable for research into autoimmune diseases.

D4476 (Casein Kinase I Inhibitor) is an effective, selective, and cell-permeant CK1 (casein kinase 1) inhibitor( IC50=300 nM in a cell-free assay).

FD44 is an inhibitor of the NCS-1/Ric8a interaction.

JPD447 is a MAC-0547630 derivative that potentiates UppS inhibitors of β-lactam antibiotics with antimicrobial activity and can be used to study bacterial infections.

Antitumor Agent-108 (Compound 5), an inhibitor of the Hyaluronic Acid (HA)-CD44 interaction, effectively disrupts cancer spheroid integrity and exhibits antiproliferative activity against cancer cells [1].

Anti-Mouse CD11a Antibody is a rat-derived IgG2b inhibitor specific to the mouse CD11a molecule.

CID44216842 (KUC103479N-02) is a potent Cdc42-selective guanine nucleotide binding lead inhibitor. The EC50s for Cdc42 WT and Cdc42Q61L mutant are 1.0 and 1.2 μM in GTP binding assay, respectively. The EC50s for Cdc42 WT and Cdc42Q61L mutant are 0.3 and 0.5 μM in GDP binding assay, respectively. Use as a molecular probe.

The Anti-CD44 Antibody (Hermes-1) is a chimeric rat-derived IgG2a, κ antibody targeting human CD44. The isotype control for the Anti-CD44 Antibody (Hermes-1) is RatIgG2akappa, Isotype Control.

Compound 4418-61-5, with CAS No. 4418-61-5, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound 4418-61-5 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound 446286-61-9, with CAS No. 446286-61-9, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound 446286-61-9 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

AZD 4407 is a potent inhibitor of 5-lipoxygenase.

DVD-445 is an effective and covalent thioredoxin reductase 1 (TrxR1) inhibitor with an IC50 of 0.60 μM. DVD-445 is a peptidomimetic compound synthesised via the Ugi reaction, featuring an electrophilic moiety and demonstrating promising anticancer potential.

ML230 is a selective ATP-binding cassette (ABC) transporter ABCG2 inhibitor. It 36-fold selective for ABCG2 over ABCB1 (EC50s: 0.13 μM and 4.65 μM, respectively).

PYZD-4409 is a selective UBA1 inhibitor with an IC50 of 20 μM. PYZD-4409 induces cell death in malignant cells and is preferentially cytotoxic to malignant cells over normal hematopoietic cells.

E3ligaseLigand 44 is a ligand for the E3 ligase and is employed in synthesizing [PROTACAR Degrader-7].

AR ligand-44 is an androgen receptor (androgen receptor) ligand that can be utilized in the synthesis of PROTACs such as [ARD-2051].

VVD-442 is a covalent RAS-PI3K inhibitor that binds covalently to cysteine at position 242 in the RAS-binding domain of PI3Kp110α, thereby inhibiting the interaction between RAS and PI3K. VVD-442 is applicable for research in cancers such as breast cancer.

AR ligand-44 TFA is an androgen receptor (AR) ligand utilized in the synthesis of PROTACs, such as ARD-2051.

D-4418 is a PDE4 inhibitor. It has been in development as a novel anti-inflammatory therapy with asthma and chronic obstructive pulmonary disease being primary indications.

ML167 (CID44968231) is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor.